Cantor Fitzgerald analyst Steve Seedhouse assumed coverage of ProQR Therapeutics (PRQR) with an Overweight rating and $8 price target ProQR is a leader in RNA editing and the initial biomarker data for its first program targeting bile acid transporter in Q4 will be an “important catalyst,” the analyst tells investors in a research note. Cantor views the company as a “pure play” on RNA editing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRQR:
- ProQR Therapeutics initiated with an Outperform at Evercore ISI
- ProQR Announces New CFO and CMO to Drive Growth
- ProQR Therapeutics appoints Hom as CFO, Lopez as CMO
- ProQR Therapeutics Advances RNA Editing Pipeline
- ProQR’s Axiomer Technology and AX-0810: A Promising Buy Rating with Increased Price Target